NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

NovaBridge BiosciencesNASDAQ: NBP

Net Debt · Q4 FY2025 · quarter ended Dec 2025

Net debt remains negative

Q4 FY2025 net debt was -$29.67M, compared with -$469.9M a year earlier.

Context

  • Net debt amounted to 79.7% of total assets at the end of Q4 FY2025, up 49.4 pp from a year earlier.
  • Net debt grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +93.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$29.67M+99.7% QoQ
Last fiscal yearDec 2025
-$29.67M+93.7% YoY
Year agoDec 2024
-$469.9M+93.7% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.7%——
1 year+93.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

Mixed currencies · from the balance sheet

Latest · FY2025
(29.67M) USD
Year-over-year change
—

Net Debt vs competitors

How NBP compares with its peers on the latest reported figures

  • NBP's Dec 2025 net debt of -$29.67M is the 7th highest of the 11 companies compared; the peer median is -$23.21M.
  • Its year-over-year change of +93.7% is the highest of 11, against a peer median of -24.4%.
  • Net debt amounts to 79.7% of total assets for NBP, versus a peer median of 13.6%.
NBP Competitors Peer median
Net Debt for NBP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GALTGalectin Therapeutics Inc.Mar 2026$121.61M +20.9%+76.0%771.7%
DRTSAlpha Tau Medical Ltd.Mar 2026$5.9M -18.9%—5.4%
DMACDiaMedica Therapeutics Inc.Mar 2026-$4.66M -104.8%—8.8%
DSGNDesign Therapeutics, Inc.Mar 2026-$10.04M +12.9%—4.4%
ENGNenGene Holdings Inc.Apr 2026-$21.58M +33.0%—7.0%
RCKTRocket Pharmaceuticals, Inc.Mar 2026-$24.85M -1.6%—8.7%
NBPNovaBridge BiosciencesDec 2025-$29.67M +93.7%—79.7%
ALTAltimmune, Inc.Mar 2026-$61.75M -30.0%—18.4%
AURAAura Biosciences, Inc.Mar 2026-$67.8M -242.7%—49.2%
ANNXAnnexon, Inc.Mar 2026-$149.77M -117.7%—57.0%
LBRXLB Pharmaceuticals Inc Common StockMar 2026-$317.21M -2931.4%—80.6%
Peer median (excluding NBP) -$23.21M-24.4%+76.0%13.6%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Cash & Equivalents552.8M3.21B291.51M498.24M30.11M
Short-term Investments118.16M235.43M20.22M767.36M30.02K
Net Receivables60.95M4.81M1.83M8.55M256.33K
Inventory4.27M(80.28M)000
Other Current Assets0242.96M15.68M10
Total Current Assets750.18M3.63B329.91M1.29B31.1M
Property, Plant & Equipment (Net)24.87M123.97M5.55M27.72M421.59K
Goodwill25.51M162.57M000
Intangible Assets18.77M118.89M000
Long-term Investments55.24M30.85M0224.98M5.32M
Tax Assets00000
Other Non-current Assets4.18M10.91M33.46M9.96M402K
Total Non-current Assets128.56M447.19M39.01M262.66M6.15M
Total Assets878.74M4.07B368.92M1.55B37.24M
Account Payables00000
Short-term Debt02.75M000
Tax Payables00000
Deferred Revenue371.66K2.19M0773.67K0
Other Current Liabilities0549.85M49.67M5.01M1.31M
Total Current Liabilities97.9M659.74M58.14M61.7M3.84M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)37.49M0106K00
Other Non-current Liabilities15.2M373.53M64.83M3.8K73.05K
Total Non-current Liabilities65.52M405.6M68.19M22.38M384.13K
Total Liabilities163.42M1.07B126.34M84.08M4.23M
Common Stock19.77K132K19K138.68K3.86K
Retained Earnings(683.21M)(6.77B)(1.26B)(9.39B)(190.47M)
Accumulated OCI(29.26M)216.72M39.77M243.66M5.94M
Other Stockholders Equity00000
Minority Interest00000
Total Equity715.33M3.01B242.58M1.47B33.02M
Total Debt17.64M38.29M3.89M28.33M438.46K
Net Debt(535.16M)(3.18B)(287.62M)(469.9M)(29.67M)

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.